TrialOncotarget2016

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Emeline Tabouret et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.